Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.
McLouth LE, Zheng Y, Smith S, Hodi FS, Rao UN, Cohen GI, Amatruda TT, Dakhil SR, Curti BD, Nakhoul I, Chandana SR, Bane CL, Marinier DE, Lee SJ, Sondak VK, Kirkwood JM, Tarhini AA, Wagner LI.
McLouth LE, et al.
Qual Life Res. 2023 Jan;32(1):183-196. doi: 10.1007/s11136-022-03226-8. Epub 2022 Aug 27.
Qual Life Res. 2023.
PMID: 36029412
Free PMC article.
Clinical Trial.
HDI = 17.1 5.4, p < .001; ipi10 = 21.8 5.0 vs. HDI p < .001) and cognitive/emotional (ipi3 = 18.6 4.4 vs. ...HDI = 42.2 2.9, p = .011; ipi10 = 39.5 7.0 vs. HDI, p < .001). Fewer ipilimumab patients reported worsening treatment-specific concern
…
HDI = 17.1 5.4, p < .001; ipi10 = 21.8 5.0 vs. HDI p < .001) and cognitive/emotional (ipi3 = 18.6 4.4 vs. ...HDI = 42.2
…